Strategic Advisors LLC Purchases Shares of 6,390 Bristol Myers Squibb Company (NYSE:BMY)

Strategic Advisors LLC acquired a new position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 6,390 shares of the biopharmaceutical company's stock, valued at approximately $390,000.

Several other large investors also recently added to or reduced their stakes in BMY. Norges Bank purchased a new stake in shares of Bristol Myers Squibb in the 4th quarter worth $1,989,525,000. Ameriprise Financial Inc. increased its position in Bristol Myers Squibb by 59.9% in the fourth quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock worth $1,814,341,000 after buying an additional 12,011,983 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its position in shares of Bristol Myers Squibb by 701.2% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,470,106 shares of the biopharmaceutical company's stock valued at $705,309,000 after buying an additional 10,913,708 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Bristol Myers Squibb by 3,880.0% during the 4th quarter. Wellington Management Group LLP now owns 5,977,505 shares of the biopharmaceutical company's stock valued at $338,088,000 after acquiring an additional 5,827,317 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in Bristol Myers Squibb during the 4th quarter worth approximately $257,618,000. 76.41% of the stock is currently owned by institutional investors.

Insider Activity at Bristol Myers Squibb

In other news, EVP Samit Hirawat purchased 4,250 shares of the business's stock in a transaction that occurred on Friday, April 25th. The shares were bought at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the acquisition, the executive vice president now owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.07% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

BMY has been the subject of a number of analyst reports. UBS Group reduced their price objective on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research note on Friday, April 11th. Argus upgraded Bristol Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Cantor Fitzgerald reiterated a "neutral" rating and set a $55.00 target price on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. The Goldman Sachs Group reissued a "neutral" rating and set a $55.00 target price (down previously from $67.00) on shares of Bristol Myers Squibb in a research note on Tuesday, April 8th. Finally, Jefferies Financial Group dropped their price target on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $58.00.

Bristol Myers Squibb Stock Performance

Shares of NYSE:BMY opened at $47.25 on Wednesday. The firm has a fifty day simple moving average of $48.49 and a two-hundred day simple moving average of $54.58. Bristol Myers Squibb Company has a 52 week low of $39.35 and a 52 week high of $63.33. The company has a quick ratio of 1.17, a current ratio of 1.28 and a debt-to-equity ratio of 2.65. The stock has a market capitalization of $96.15 billion, a P/E ratio of 17.70, a PEG ratio of 1.42 and a beta of 0.38.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The company had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. During the same quarter last year, the business posted ($4.40) earnings per share. The firm's revenue was down 5.6% on a year-over-year basis. On average, analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.25%. Bristol Myers Squibb's dividend payout ratio is currently 92.88%.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.